Value of 18F-Fluordeoxyglucose Positron Emission Tomography/ Computed Tomography and Molecular Tumor Characterisation in Preoperative Staging og Postoperative Control of Colon Cancer
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Naestved Hospital
- Enrollment
- 66
- Primary Endpoint
- time to recurrence
Study Overview
Brief Summary
The investigators are investigating the usefulness of 18F-Fluordeoxyglucose Positron Emission Tomography/ Computed Tomography (18F-FDG PET/CT) for staging and follow-up of colon cancer. Furthermore, the investigators combine 18F-FDG PET findings with clinical and histopathological features, circulating tumor cell (CTC) analyses, tumor gene expression and measurements of circulating cancer biomarkers sUPAR, TIMP-1 and CEA in order to predict tumor recurrence.
The investigators hypothesis: The combination of functional imaging by 18F-FDG PET/CT and pre-existing and evolving molecular biomarkers will optimize tumor characterization, staging of disease and early detection of recurrence.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •clinical or histological diagnosis of malignant clonic neoplasm (distance of more than 15 cm from anal ring)
- •18 years of age or older
- •written informed consent
Exclusion Criteria
- •known malignant disease other than colon cancer
- •known metastatic disease
- •impairment of renal function
- •allergy to CT contrast agents
- •body weight of more than 150 kg
- •claustrophobia
Outcomes
Primary Outcomes
time to recurrence
Secondary Outcomes
No secondary outcomes reported
Investigators
Bodil Elisabeth Engelmann
MD, research fellow
Naestved Hospital